Humana Inc. Raises FY 2025 Adjusted EPS Guidance to $17.00, Reports 2Q25 GAAP EPS of $4.51 and Adjusted EPS of $6.27, Increases Revenue Guidance to At Least $128 Billion

Reuters
Jul 30
Humana Inc. Raises FY 2025 Adjusted EPS Guidance to $17.00, Reports 2Q25 GAAP EPS of $4.51 and Adjusted EPS of $6.27, Increases Revenue Guidance to At Least $128 Billion

Humana Inc. reported its financial results for the second quarter of 2025, showcasing significant performance metrics and updates. The company announced earnings per share $(EPS)$ of $4.51 on a GAAP basis, with an adjusted EPS of $6.27 for the quarter. Year-to-date EPS stood at $14.81 on a GAAP basis and $17.85 on an adjusted basis. The insurance segment benefit ratio was reported at 89.9%, aligning with the company's previous expectation of approximately 90%. Humana revised its full-year 2025 GAAP EPS guidance to approximately $13.77, down from the prior estimate of approximately $14.68. However, it raised its adjusted FY 2025 EPS guidance to approximately $17.00, from the previous guidance of approximately $16.25. In terms of revenue, Humana increased its full-year 2025 consolidated revenue guidance to at least $128 billion, up from the previous range of $126 billion to $128 billion. The company also affirmed its FY 2025 insurance segment benefit ratio guidance range of 90.1% to 90.5%. Humana highlighted the strategic focus on investing in improved outcomes, operational excellence, and enhancing customer and investor experiences.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humana Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250730069182) on July 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10